Evaxion A/S (NASDAQ:EVAX) Issues Quarterly Earnings Results

Evaxion A/S (NASDAQ:EVAX) issued its quarterly earnings results on Thursday. The company reported $0.30 EPS for the quarter, reports.

Evaxion A/S Trading Down 5.3%

Shares of EVAX traded down $0.18 during midday trading on Friday, reaching $3.22. The stock had a trading volume of 29,981 shares, compared to its average volume of 25,745. The firm has a market cap of $26.85 million, a PE ratio of -2.44 and a beta of 0.28. The firm has a 50 day simple moving average of $3.90 and a 200-day simple moving average of $4.61. Evaxion A/S has a one year low of $1.20 and a one year high of $12.15.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on EVAX. Maxim Group started coverage on Evaxion A/S in a report on Thursday, February 19th. They issued a “buy” rating and a $10.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Evaxion A/S in a research report on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Evaxion A/S currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.75.

Hedge Funds Weigh In On Evaxion A/S

A number of hedge funds and other institutional investors have recently bought and sold shares of EVAX. SmartHarvest Portfolios LLC bought a new stake in Evaxion A/S in the fourth quarter valued at approximately $72,000. Northwestern Mutual Wealth Management Co. bought a new position in shares of Evaxion A/S during the 4th quarter worth approximately $38,000. Finally, Wesbanco Bank Inc. acquired a new position in shares of Evaxion A/S during the 4th quarter worth approximately $48,000. Institutional investors own 11.04% of the company’s stock.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.